- Dr. Smith's Diaper Rash Ointment
- CFC inhalers to be phased out by end of year, FDA says
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals has launched a drug for treating chronic obstructive pulmonary disease, the company said Tuesday.
BI Pharmaceuticals announced the launch of Combivent Respimat (ipratropium bromide and albuterol), calling it a propellant-free inhaler that uses a slow-moving mist to deliver the same active ingredients as the Combivent metered dose inhaler, requiring one inhalation per dose, compared with Combivent MDI's two inhalations.
"Combivent Respimat is a testament to our company's commitment to developing advancements for peole living with respiratory disease," BI Pharmaceuticals VP clinical development and medical affairs Tunde Otulana said. "We are continuing to examine the potential of several late-stage investigational compounds also delivered by the Respimat inhaler."